TickerFacts.

Aardvark Therapeutics, Inc. (AARD): R&D Expense

Annual figures by period end, from SEC filings.

$48.94M
Year ended 2025-12-31
$55.06M
Trailing 12 months to 2026-06-30
2024-12-31: $17.36M2025-12-31: $48.94M$48.94M
2024-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$48.94M+181.8%2026-03-23, From 2025-01-01
2024-12-31$17.36Mn/a2026-03-23, From 2024-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Aardvark Therapeutics, Inc. (AARD)2025-12-31$48.94M+181.8%
Abbott Laboratories (ABT)2025-12-31$2.94B+3.4%
Bristol Myers Squibb Co (BMY)2025-12-31$9.95B-10.8%
Eli Lilly & Co (LLY)2025-12-31$13.34B+21.3%
Pfizer Inc (PFE)2025-12-31$10.44B-3.6%
Johnson & Johnson (JNJ)2025-12-28$14.66B-14.9%
Nature's Sunshine Products Inc (NATR)2025-12-31$1.90M+11.8%
Merck & Co., Inc. (MRK)2025-12-31$15.79B-12.0%
Provectus Biopharmaceuticals, Inc. (PVCT)2025-12-31$1.90M-7.5%

Compare AARD, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗